WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024.

Press Release
VELIZY-VILLACOUBLAY, France — May 13, 2024

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Encore Capital Group, Inc. (Nasdaq: ECPG) (the “Company”) today announced its intention to offer, subject to market and other conditions, $400.0 million aggregate principal amount of senior secured notes due 2030 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and outside the United States to non-U.S. persons (within the meaning of Regulation S under the Securities Act).

CARLSBAD, Calif. , May 13, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it has scheduled a conference call to update investors and discuss its first quarter fiscal 2024 financial results that ended March 31, 2024. Management will host the conference call on Tuesday May 14, 2024 at 11:00 a.m. Eastern Time.

Saskatoon, SK., May 13, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, announced today that it will host a shareholder update call on May 14, 2024, at 2:30 PDT / 5:30 p.m. EDT.

MONTREAL, May 13, 2024 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL; TSX and NYSE) today announced that it has published an investor presentation, entitled “Successfully Driving Long-Term Value for All Shareholders”, in connection with its upcoming 2024 Annual Meeting of Shareholders (the “2024 Annual Meeting”) to be held on May 28, 2024. The investor presentation will be available at http://www.futureofgildan.com and on the Company’s 2024 Annual Meeting page.

– NDA for etripamil in PSVT resubmitted in 1Q 2024
– Cash resources as of March 31, 2024 expected to fund operations into 2026
– Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR is progressing

SCOTTSDALE, Ariz., May 13, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation’s largest provider of chiropractic care through The Joint Chiropractic^® network, signed an agreement engaging Capstone Partners, a full-service middle market investment bank with specialization in refranchising.

FORM 8.3

- First Quarter 2024 Total Revenue More Than Doubled Year-over-Year to $21.5 Million -

― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ―

 Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively

First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024

Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept data from Part A of the trial expected in 2H 2025

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) -- The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced that its May 2024 distribution of $0.0946 per unit has been declared and is payable to unitholders of record as at May 21, 2024. The May 2024 distribution will be paid on May 31, 2024.

 - Geoffrey Morphy terminated as CEO and Nicolas Bonta appointed on interim basis -
- CEO Executive search nearing completion -

--NDA Resubmitted; FDA Action Expected in Early Q4 24--

--Cash Runway into 2025, including through Potential FDA Approval--